HK/China Healthcare Analyst (ex-Fosun Pharma)

Xinyao (Criss) Wang

Over 15 years' experience in both finance and healthcare, covering clinic operations, investment and equity research in both China and overseas.

Pre-IPO Xunfei Healthcare Technology (PHIP Updates) - Profitability Are Always the Pain Points

Pre-IPO Bloks Group (PHIP Updates) - Some Points Worth the Attention

Pre-IPO Sunshine Lake Pharma - “Outdated” Pipeline Is Difficult to Obtain Decent Valuation

Pre-IPO Xiaocaiyuan International Holding - A "Dark Horse" In Mass Chinese Cuisine Market

Pre-IPO Mao Geping Cosmetics - Potential Risks Behind High Gross Margins

Pre-IPO S.F. Holding (6936 HK) - Thoughts on Valuation and the Outlook

Greatview Aseptic Packaging (468.HK) Update - Some New Information Worth the Attention

Ping An Healthcare and Technology (1833 HK) - Privatization Ahead?

Equity Capital Markets

Xiaocaiyuan International Holding / Equity Capital Markets

Xiaocaiyuan International Holding (XCY HK)

<ul>
<li>The financial data for 2024 has already shown investors weak growth signal.After IPO, Xiaocaiyuan may face stricter scrutiny from investors and the market in terms of its sustainable performance growth.</li>
<li>It’s not easy for Xiaocaiyuan to find new growth points. Catering companies commonly face problems such as performance fluctuations and uncertain profitability, which has left their share price underperforming.</li>
<li>Post investment valuation has already reached RMB10 billion, which far exceeds the market value of A-share peers. Due to concerns on the outlook, valuation performance after IPO could be lower-than-expected.</li>
</ul>


The financial data for 2024 has already shown investors weak growth signal.After IPO, Xiaocaiyuan may face stricter scrutiny from investors and the market in terms of its sustainable performance growth.
It’s not easy for Xiaocaiyuan to find new growth points. Catering companies commonly face problems such as performance fluctuations and uncertain profitability, which has left their share price underperforming.
Post investment valuation has already reached RMB10 billion, which far exceeds the market value of A-share peers. Due to concerns on the outlook, valuation performance after IPO could be lower-than-expected.


Pre-IPO Xiaocaiyuan International Holding (PHIP Updates) - Some Points Worth the Attention